Corvus Pharmaceuticals Inc (CRVS) Company Profile & Statistics

Corvus Pharmaceuticals Inc
CRVS
(Nasdaq - US)
Open
9.07
+0.13 (+1.45%)
in:usd•As of: Nov 22, 2024 13:12 UTC -5
Open
8.97
High
9.17
Low
8.95

About Corvus Pharmaceuticals Inc

CEO

Richard A. Miller

Headquarters

863 mitten road, suite102

burlingame, ca 94010, united states

Auditor

PricewaterhouseCoopers LLP

Employees

Share Holders

Website

www.corvuspharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.

Corvus Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	582.84M
Enterprise Value	578.16M
Enterprise Value/EBITDA (ttm)	-22.21
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	42.34
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-70.71%
Return on Invested Capital (ttm)	-366.70%
Return on Assets (ttm)	-45.90%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-26.03M
Net Income Avi to Common (ttm)	-56.83M
Diluted EPS (ttm)	-0.93

Share Statistics

Beta (5Y Monthly)	1.05
52-Week Change	504.67%
S&P500 52-Week Change	30.98%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	64.26M
Dividend Yield	0.00%
Float ⁴	44.15M
% Held by Insiders	31.30%
% Held by Institutions	46.64%

Balance Sheet

Total Cash (mrq)	41.65M
Total Cash Per Share (mrq)	0.65
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	0.92%
Quick Ratio (mrq)	0.92%
Book Value Per Share (mrq)	0.20

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.25
Free Cash Flow (ytd)	-16.96M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Corvus Pharmaceuticals Inc

Trade With A Regulated Broker